University Hospital Center of Pointe-à-Pitre
Pointe-à-Pitre, 97159, Guadeloupe
NCT Number: NCT03362762
Type 2 diabetes is a major problem of public health in the French West Indies, with an estimated prevalence of 8%, twice more than in France. In Guadeloupe, according to the statistical data of hospital morbidity in 2004, 2643 hospital stays were diagnosed with diabetes. These cases mainly concerned woman (62%) and the elderly, from 45 to 74 years old (67%).
The main objective of this research is to describe the insulin protocol used in Guadeloupe for treated type 2 diabetes patients and their characteristics:
* The duration of the type 2 diabetes * Time elapsing between the diagnosis and the treatment by insulin * Where the follow up care took place * Existence of complications
Secondary objectives were to describe the link between the HbA1c rate and the insulin therapy protocol. And also to present the main inconveniences expressed by patients and their degree of autonomy.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Pointe-à-Pitre, 97159, Guadeloupe
Nowadays the set up for insulin treatment is available in general practitioners' offices. However, it is restrained by the reticence of patients and physicians. For type 2 diabetes, insulin therapy is well managed and there is ongoing progress. But there are still some questions about the effect of the treatment in the everyday life of patients: culture, fear, material resources, necessity of education.
Ignorance and prejudices on insulin injection are still prevalent and often it delays for more than a year the time when patients have to switch an insulin treatment for unbalanced chronic disorder.
Type 2 diabetes patients think that the treatment is heavy, can lead to serious hypoglycemia, is uncomfortable for family and can cause fear.
Education of the patients can reduce ignorance and prejudices about insulin treatment.
Nowadays studies show that diabetes patients want to be more involved in the decisions linked to their treatment which impact their perception of the disease and the treatment.
Auto measurement of glycaemia can help the patient better manage his disease and make him understand the importance of controlling his glycaemia levels.
This study could allow to:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The physician or the endocrinologist will see the patient during his consultation. The pharmacist will see the patient when he goes to the pharmacy for an insulin treatment. In each case, the patient will be informed about the study, about the medical data that will be collected anonymously. The date will be strictly confidential and under medical secrecy. Then the patient will meet the physician during another consultation at the University Hospital Center of Guadeloupe, in order to collect information's on a questionnaire. Otherwise, the physician can meet the patient at his home, in case he can't move to the University Hospital Center of Guadeloupe.
Time frame: Trough study completion, an average of 2 years
A descriptive analysis will be done on the population concerned by the study, for the socio demographic, clinical and therapeutic characteristics.
Time frame: Trough study completion, an average of 2 years
Sreening of HbAC
Centre Hospitalier Universitaire de la Guadeloupe
Other
Acronym: DT2IT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05161741
Adverse Drug Event, Chemically-Induced Disorders
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT04522882
Diabetes Mellitus, Diabetes Mellitus, Type 2
Meylan, France
View Trial DetailsNCT06311019
Diabetes Mellitus, Diabetes Mellitus, Type 2
Aarhus, Denmark
View Trial DetailsNCT05785832
Diabetes Mellitus, Diabetes Mellitus, Type 2
Newport Beach, California, United States
View Trial Details